ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 893

Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44

Tadashi Yasuda, Dept of Sports Medicine, Tenri University, Tenri, Japan

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: chondrocytes, hyaluronate, matrix metalloproteinase (MMP), signal transduction and type II collagen

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Some proteolytic products of cartilage matrix may contribute to cartilage destruction through their catabolic activities. Recently, we have found that a 24-mer synthetic peptide of type II collagen named CB12-II stimulates type II collagen cleavage with induction of matrix metalloproteinase (MMP)-13 in cartilage explant culture. Although the intracellular signaling that leads to cartilage destruction is mediated by a cluster of catabolic pathways including nuclear factor-κB (NF-κB), the effect of CB12-II on NF-κB remains unclear.

Hyaluronan (HA) of high molecular weight is widely used in the treatment of osteoarthritis (OA) by intra-articular injection. An increasing body of evidence indicates that HA suppresses catabolic actions by proinflammatory cytokines like interleukin-1 and matrikines such as fibronectin fragments. However, little is known of HA effect on actions of CB12-II through interaction with HA receptor such as CD44.

This study was aimed to examine activation of NF-κB in association with MMP-13 production by CB12-II and its inhibition by HA in chondrocytes.

Methods:

Cartilage explants harvested from OA knee joints or isolated chondrocytes in monolayer were incubated with CB12-II or its scramble peptide with or without pretreatment with 2700 kDa HA. In another set of experiments, following preincubation with anti-CD44 antibody or non-specific IgG, cartilage explants were incubated with or without HA, followed by coincubation with CB12-II or the scramble peptide.

Enzyme-linked immunosorbent assays for phosphorylated p65 NF-κB and MMP13 were performed using total cell lysates and culture supernatants, respectively.

Results:

When cartilage explants or chondrocytes in monolayer were incubated with CB12-II, the type II collagen peptide activated NF-κB in association with enhanced MMP-13 production. Inhibition studies with the specific inhibitor indicated the requirement of NF-κB for CB12-II-induced MMP-13 production. Pretreatment with HA resulted in significant suppression of CB12-II-stimulated MMP-13 production in cartilage as well as in chondrocyte monolayer cultures. HA suppressed NF-κB activation by CB12-II, leading to a decrease in MMP-13 production. Anti-CD44 antibody reversed HA effect on CB12-II action.

Conclusion:

The present study clearly demonstrated that HA suppressed CB12-II-activated NF-κB via CD44 in OA articular chondrocytes, leading to decreased MMP-13 production. HA could down-regulate the catabolic action of type II collagen fragments in osteoarthritic joints through the mechanism demonstrated in this study.


Disclosure:

T. Yasuda,
None;

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2012

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nuclear-factor-%ce%bab-activation-by-type-ii-collagen-peptide-in-osteoarthritic-chondrocytes-its-inhibition-by-hyaluronan-via-cd44/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology